source
- AstraZeneca’s GLP-1 obesity pill shows 10.5% average weight loss after six months in Phase 2 trialAstraZeneca reported data from its Phase 2 study of a GLP-1 based oral obesity treatment. The trial showed participants lost an average of 10.5% of body weight after six months of therapy. The re…
- Treeline Biosciences to go public via reverse merger with Standard BioTools, securing runway to 2029Treeline Biosciences announced that it will become a publicly traded company through a reverse merger with Standard BioTools. The transaction is expected to list the combined entity on a U.S. excha…